Of note, recent work demonstrated that the TLR7/8/9 antagonist IMO-8503 improved lean mass retention and decreased muscle catabolism in the Lewis lung carcinoma (LLC) cachexia model, without any changes to tumor size37. Here, TLR7 is linked to neoplasm.